Impact of 5-HT3 receptor antagonist (5HT3-RA) selection within triple antiemetic regimens on the risk of uncontrolled chemotherapy-induced nausea and vomiting with highly emetogenic chemotherapy (HEC) in breast cancer patients.

被引：0
|
作者：
Jackson, J.
Jain, G.
Balu, S.
Buchner, D.
Schwartzberg, L. S.
机构：
[1] Xcenda, Palm Harbor, FL USA
[2] Eisai Inc, Woodcliff Lake, NJ USA
[3] West Clin, Memphis, TN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.e16519
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16519
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Impact of 5-HT3 RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting
    Schwartzberg, Lee
    Jackson, James
    Jain, Gagan
    Balu, Sanjeev
    Buchner, Deborah
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2011, 11 (04) : 481 - 488
  • [2] IMPACT OF 5-HT3 RECEPTOR ANTAGONIST SELECTION WITHIN TRIPLE ANTIEMETIC REGIMENS ON THE RISK OF UNCONTROLLED CHEMOTHERAPY-INDUCED NAUSEA IN PATIENTS WITH CANCER TREATED WITH HIGHLY EMETOGENIC CHEMOTHERAPY
    Schwartzberg, L.
    Jackson, J.
    Jain, G.
    Balu, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A434 - A434
  • [3] ONDANSETRON - A SEROTONIN RECEPTOR (5-HT3) ANTAGONIST FOR ANTINEOPLASTIC CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING
    KOHLER, DR
    GOLDSPIEL, BR
    [J]. DICP-THE ANNALS OF PHARMACOTHERAPY, 1991, 25 (04): : 367 - 380
  • [4] EFFECT OF ANTIEMETIC PROPHYLAXIS AGAINST CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING WITH 5-HT3 RECEPTOR ANTAGONISTS IN PATIENTS WITH LYMPHOMA
    Lin, S. J.
    Hatoum, H. T.
    Balu, S.
    [J]. VALUE IN HEALTH, 2011, 14 (07) : A434 - A434
  • [5] QoL evaluation of olanzapine for chemotherapy-induced nausea and vomiting comparing with 5-HT3 receptor antagonist
    Liu, J.
    Tan, L.
    Zhang, H.
    Li, H.
    Liu, X.
    Yan, Z.
    Chen, J.
    Yang, H.
    Zhang, D.
    [J]. EUROPEAN JOURNAL OF CANCER CARE, 2015, 24 (03) : 436 - 443
  • [6] 5-HT3 ANTAGONIST ONDANSETRON FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN AN OUTPATIENT POPULATION
    CASPER, J
    CASPER, S
    KOHNEWOMPNER, CH
    BOKEMEYER, C
    HECKER, H
    SCHMOLL, HJ
    [J]. INTERNATIONAL JOURNAL OF ONCOLOGY, 1994, 4 (06) : 1283 - 1289
  • [7] Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
    Swu-Jane Lin
    Hind T Hatoum
    Deborah Buchner
    David Cox
    Sanjeev Balu
    [J]. BMC Health Services Research, 12
  • [8] Impact of 5-HT3 receptor antagonists on chemotherapy-induced nausea and vomiting: a retrospective cohort study
    Lin, Swu-Jane
    Hatoum, Hind T.
    Buchner, Deborah
    Cox, David
    Balu, Sanjeev
    [J]. BMC HEALTH SERVICES RESEARCH, 2012, 12
  • [9] Efficacy of antiemetic regimens for prevention and treatment of chemotherapy-induced nausea and vomiting in patients of breast cancer receiving highly emetogenic chemotherapy
    Vij, Soumya
    Dhasmana, Dilip Chander
    Bala, Suman
    Verma, Sanjiv Kumar
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (06) : 819 - 824
  • [10] Review of palonosetron: emerging data distinguishing it as a novel 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting
    Saito, Mitsue
    Tsukuda, Mamoru
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (06) : 1003 - 1014
12345